Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Mesoblast International Sàrl has 4 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed across 4 examiners and 4 art units, indicating that the current prosecution workload is spread rather than concentrated in a single examination channel.
TIWARI, VYOMA SHUBHAM is the busiest examiner, with 1 pending matter. Counsel should therefore review each file independently and avoid assuming that developments before one examiner or art unit will control the broader portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 1 | 32.1% | +47.4% |
| THUESON, HANNA MARIE | 1 | 76.7% | +28.2% |
| GU, QINHUA | 1 | 76.2% | +27.1% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18723204 | METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE | TIWARI, VYOMA SHUBHAM | — |
| 18556827 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | THUESON, HANNA MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17612939 | FUNCTIONAL RECOVERY FROM CEREBRAL INFARCTION | BARRON, SEAN C | 2d overdue |
| 18723204 | METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE | TIWARI, VYOMA SHUBHAM | — |
| 18556827 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | THUESON, HANNA MARIE | — |
| 18262505 | OPIOID SPARING COMPOSITIONS AND METHODS OF USING THE SAME | GU, QINHUA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1638 | 1 |
| 1633 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723204 | METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE | TIWARI, VYOMA SHUBHAM | 1634 | §102§103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18556827 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | THUESON, HANNA MARIE | 1638 | §102§103§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18262505 | OPIOID SPARING COMPOSITIONS AND METHODS OF USING THE SAME | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Jul 21, 2023 |
| 17612939 | FUNCTIONAL RECOVERY FROM CEREBRAL INFARCTION | BARRON, SEAN C | 1653 | §103 | Non-Final OA | 2d overdue | Pending | Nov 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMesoblast International Sárl has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Vyoma Shubham Tiwari has the most, with 1 of Mesoblast International Sárl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
